Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 6/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CD38 | P28907 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1506153 | 0.83 | RIPK1 (0.39) | RIPK1ERBB2P2RX7MAPTCD38 | |
| SCHEMBL3773575 | 0.79 | KCNJ6 (0.37) | P2RX7MAPTKDM4E | |
| SCHEMBL1506082 | 0.75 | P2RX7 (0.45) | RIPK1ERBB2P2RX7 | |
| SCHEMBL3782940 | 0.74 | ULK1 (0.41) | P2RX7P2RX3CD38 | |
| SCHEMBL1506045 | 0.73 | CYP1A2 (0.40) | RIPK1ERBB2P2RX7MAPTKDM4E | |
| SCHEMBL3774598 | 0.73 | CYP1A2 (0.41) | MAPTP2RX3KDM4E | |
| SCHEMBL1506203 | 0.72 | RIPK1 (0.44) | RIPK1MAPTP2RX3CD38 | |
| SCHEMBL10011414 | 0.71 | KMT2A (0.40) | RIPK1ERBB2P2RX7CD38 | |
| SCHEMBL1506292 | 0.70 | RIPK1 (0.39) | RIPK1MAPTP2RX3CD38 | |
| SCHEMBL3032270 | 0.67 | LMNA (0.39) | RIPK1P2RX3KDM4ECD38 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778974-B2 | Trisubstituted 1,2,4 triazoles | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-15 | — | — | US | claimed |
| EP-2257535-B1 | TRISUBSTITUTED 1,2,4-TRIAZOLES AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-11-06 | — | — | EP | claimed |
| CN-102066343-A | Trisubstituted 1,2, 4-triazoles as nicotinic acetylcholine receptor modulators | JANSSEN PHARMACEUTICA NV | 2011-05-18 | — | — | CN | claimed |
| US-20100324053-A1 | TRISUBSTITUTED 1,2,4 TRIAZOLES | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | claimed |
| EP-2257535-B1 | TRISUBSTITUTED 1,2,4-TRIAZOLES AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324053-A1 | TRISUBSTITUTED 1,2,4 TRIAZOLES | CHRNA1, CHRNA5, CHRNE | RIPK1 2991/4885ERBB2 740/4885P2RX7 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.